162 related articles for article (PubMed ID: 15195127)
21. Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans.
Kittles RA; Panguluri RK; Chen W; Massac A; Ahaghotu C; Jackson A; Ukoli F; Adams-Campbell L; Isaacs W; Dunston GM
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):943-7. PubMed ID: 11535545
[TBL] [Abstract][Full Text] [Related]
22. A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss.
Sata F; Yamada H; Yamada A; Kato EH; Kataoka S; Saijo Y; Kondo T; Tamaki J; Minakami H; Kishi R
Mol Hum Reprod; 2003 Nov; 9(11):725-8. PubMed ID: 14561815
[TBL] [Abstract][Full Text] [Related]
23. [Association between the polymorphism of CYP17 gene and risk of prostate cancer in chinese vigurs men].
Guli MR; Wang JQ; Zhang JX; Deng G
Zhonghua Nan Ke Xue; 2006 Feb; 12(2):120-2. PubMed ID: 16519145
[TBL] [Abstract][Full Text] [Related]
24. CYP17 promotor polymorphism and ovarian cancer risk.
Spurdle AB; Chen X; Abbazadegan M; Martin N; Khoo SK; Hurst T; Ward B; Webb PM; Chenevix-Trench G
Int J Cancer; 2000 May; 86(3):436-9. PubMed ID: 10760835
[TBL] [Abstract][Full Text] [Related]
25. A polymorphism in the CYP17 gene and risk of prostate cancer.
Stanford JL; Noonan EA; Iwasaki L; Kolb S; Chadwick RB; Feng Z; Ostrander EA
Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):243-7. PubMed ID: 11895872
[TBL] [Abstract][Full Text] [Related]
26. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T
Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis.
Cai L; Huang W; Chou KC
Protein Pept Lett; 2012 Jan; 19(1):62-9. PubMed ID: 21919858
[TBL] [Abstract][Full Text] [Related]
28. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
[TBL] [Abstract][Full Text] [Related]
29. CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.
Verla-Tebit E; Wang-Gohrke S; Chang-Claude J
Breast Cancer Res; 2005; 7(4):R455-64. PubMed ID: 15987450
[TBL] [Abstract][Full Text] [Related]
30. CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients.
Chakraborty A; Murthy NS; Chintamani C; Bhatnagar D; Mohil RS; Sharma PC; Saxena S
J Hum Genet; 2007; 52(2):159-165. PubMed ID: 17235448
[TBL] [Abstract][Full Text] [Related]
31. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Allen NE; Forrest MS; Key TJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
[TBL] [Abstract][Full Text] [Related]
32. [Association between polymorphism of CYP17 gene and serum hormone concentrations in aged men].
Wang JQ; Gu X; Chen JC; Sun XQ; Mu HT; Wei ZH; Li M; Xin DQ; Na YQ
Zhonghua Nan Ke Xue; 2005 Jun; 11(6):442-4. PubMed ID: 15999490
[TBL] [Abstract][Full Text] [Related]
33. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer.
Antognelli C; Mearini L; Talesa VN; Giannantoni A; Mearini E
Prostate; 2005 May; 63(3):240-51. PubMed ID: 15538743
[TBL] [Abstract][Full Text] [Related]
34. The CYP17 MspA1 polymorphism is not associated with an increased risk of uterine leiomyomas in a Japanese population.
Tsujino T; Ohara N; Yoshida S; Kennedy S; Takemura N; Deguchi M; Maruo T
Gynecol Endocrinol; 2006 Feb; 22(2):87-91. PubMed ID: 16603433
[TBL] [Abstract][Full Text] [Related]
35. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.
Spurdle AB; Hopper JL; Dite GS; Chen X; Cui J; McCredie MR; Giles GG; Southey MC; Venter DJ; Easton DF; Chenevix-Trench G
J Natl Cancer Inst; 2000 Oct; 92(20):1674-81. PubMed ID: 11036113
[TBL] [Abstract][Full Text] [Related]
36. Polymorphism in the Androgen Biosynthesis Gene (CYP17), a Risk for Prostate Cancer: A Meta-Analysis.
Effah CY; Wang L; Agboyibor C; Drokow EK; Yu S; Wang W; Wu Y
Am J Mens Health; 2020; 14(5):1557988320959984. PubMed ID: 32964792
[TBL] [Abstract][Full Text] [Related]
37. The T/C polymorphism of the CYP17 gene and G/A polymorphism of the CYP19 gene in endometrial cancer.
Szyllo K; Smolarz B; Romanowicz-Makowska H; Lewy J; Kulig B
J Exp Clin Cancer Res; 2006 Sep; 25(3):411-6. PubMed ID: 17167982
[TBL] [Abstract][Full Text] [Related]
38. A2 allele polymorphism of the CYP17 gene and prostate cancer risk in an iranian population.
Karimpur-Zahmatkesh A; Farzaneh F; Pouresmaeili F; Hosseini J; Azarghashb E; Yaghoobi M
Asian Pac J Cancer Prev; 2013; 14(2):1049-52. PubMed ID: 23621184
[TBL] [Abstract][Full Text] [Related]
39. [A case-control study of environmental and genetic factors and prostate cancer in Guangdong].
Wu YJ; Liang CH; Zhou FJ; Gao X; Chen LW; Liu Q
Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Jul; 43(7):581-5. PubMed ID: 19954068
[TBL] [Abstract][Full Text] [Related]
40. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
